Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$12.7 million.

  • Anika Therapeutics' Cash from Financing Activities rose 99.67% to -$13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 51.09%. This contributed to the annual value of -$12.7 million for FY2024, which is 101.28% down from last year.
  • As of FY2024, Anika Therapeutics' Cash from Financing Activities stood at -$12.7 million, which was down 101.28% from -$6.3 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Cash from Financing Activities registered a high of -$3.8 million during FY2020, and its lowest value of -$12.7 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is -$8.0 million, with a median of -$6.3 million in 2023.
  • In the last 5 years, Anika Therapeutics' Cash from Financing Activities surged by 53.65% in 2020 and then tumbled by 101.28% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Cash from Financing Activities stood at -$3.8 million in 2020, then crashed by 79.62% to -$6.8 million in 2021, then climbed by 28.43% to -$4.9 million in 2022, then plummeted by 30.34% to -$6.3 million in 2023, then slumped by 101.28% to -$12.7 million in 2024.